Wednesday, June 10, 2026

pharma · Chronic kidney disease · Advanced solid tumors

Bayer

Bayer clinical programs — 24 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE HQ
97,894 Employees
EMA registrant Type
Company details
Status
Public
HQ
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
Employees
97,894
Programs
47
Drugs
62
Patents
5
Intelligence · Clinical Programs

Bayer projects

24 ClinicalTrials.gov programs sponsored by Bayer.

Bayer has 24 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 20511

    Bayer AG

    Prostate cancer

    phase 1 other active

    1 trial
  2. 21820

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial
  3. 21948

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial
  4. 22127

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial
  5. 22128

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial
  6. 22231

    Bayer AG

    Advanced solid tumors, Non-small cell lung cancer

    phase 1 other active

    1 trial
  7. 22262

    Bayer AG

    hepatocellular carcinoma (HCC)

    phase 1 other active

    1 trial
  8. 22265

    Bayer AG

    Coagulopathy, Sepsis

    phase 1 other active

    1 trial
  9. 22342

    Bayer AG

    Heart failure in children

    phase 1 other active

    1 trial
  10. 22375

    Bayer AG

    Prevention of ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy

    phase 1 other active

    1 trial
  11. 22534

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial
  12. 22537

    Bayer AG

    Soil-transmitted helminth infection, Onchocerciasis (river blindness)

    phase 1 other active

    1 trial
  13. 22597

    Bayer AG

    Chronic kidney disease, Coronary artery disease

    phase 1 other active

    1 trial
  14. 22598

    Bayer AG

    Chronic Kidney Disease, Arterial hypertension

    phase 1 other active

    1 trial
  15. 22600

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial
  16. 22665

    Bayer AG

    Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

    phase 1 other active

    1 trial
  17. 22676

    Bayer AG

    Advanced solid tumors harboring KRAS G12C mutation

    phase 1 other active

    1 trial
  18. 22700

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial
  19. 22723

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial
  20. 22806

    Bayer AG

    atrial fibrillation, transient ischemic attack (TIA), ischemic stroke

    phase 1 other active

    1 trial
  21. 22819

    Bayer AG

    Cardiac arrhythmia

    phase 1 other active

    1 trial
  22. 22967

    Bayer AG

    Vasodilatory shock

    phase 1 other active

    1 trial
  23. A study to learn how safe the study drug BAY... for Advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial
  24. Asundexian Bayer 10mg Granules, BAY 2433334

    Bayer AG

    Prevention of thromboembolic events

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bayer have?

24 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.